Tamar Securities LLC Acquires 2,211 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Tamar Securities LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 16.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,492 shares of the biopharmaceutical company's stock after acquiring an additional 2,211 shares during the period. Regeneron Pharmaceuticals comprises approximately 2.3% of Tamar Securities LLC's portfolio, making the stock its 24th largest position. Tamar Securities LLC's holdings in Regeneron Pharmaceuticals were worth $16,286,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. SteelPeak Wealth LLC increased its stake in Regeneron Pharmaceuticals by 173.0% in the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company's stock valued at $1,148,000 after purchasing an additional 692 shares during the period. Atria Investments Inc increased its holdings in shares of Regeneron Pharmaceuticals by 12.2% in the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company's stock valued at $8,317,000 after purchasing an additional 941 shares in the last quarter. Tri Locum Partners LP increased its holdings in Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company's stock valued at $18,410,000 after buying an additional 8,949 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of Regeneron Pharmaceuticals by 23.2% in the 1st quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company's stock worth $28,218,000 after acquiring an additional 5,495 shares during the period. Finally, Tidal Investments LLC increased its stake in Regeneron Pharmaceuticals by 16.8% in the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company's stock valued at $4,774,000 after purchasing an additional 711 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on REGN shares. Cantor Fitzgerald reissued a "neutral" rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, September 16th. Royal Bank of Canada boosted their price target on Regeneron Pharmaceuticals from $1,252.00 to $1,260.00 and gave the stock an "outperform" rating in a report on Friday, October 4th. StockNews.com raised Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, October 9th. Leerink Partners reissued a "market perform" rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Finally, Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,137.00 and set a "buy" rating on the stock in a research note on Wednesday. One research analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1,116.00.

Regeneron Pharmaceuticals Trading Down 1.0 %

Shares of Regeneron Pharmaceuticals stock traded down $9.73 during trading on Thursday, hitting $998.23. 739,635 shares of the company were exchanged, compared to its average volume of 494,416. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The firm has a market capitalization of $109.99 billion, a P/E ratio of 29.51, a price-to-earnings-growth ratio of 3.45 and a beta of 0.12. The firm's fifty day moving average price is $1,114.69 and its 200 day moving average price is $1,039.93. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to analysts' expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company's revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the firm earned $8.79 earnings per share. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.82 earnings per share for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company's stock, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company's stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Jason Pitofsky sold 487 shares of the firm's stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now owns 4,204 shares of the company's stock, valued at approximately $4,498,280. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.